Cargando…
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells
BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are among the major obstacles that adjuvants for cancer vaccines have to overcome. These cells cross-present tumor-associated antigens (TAA) to naive T lymphocytes with a tolerogenic outcome. Very Small Size Proteoliposomes (VSSP) is used as adjuv...
Autores principales: | Fernández, Audry, Oliver, Liliana, Alvarez, Rydell, Hernández, Arletty, Raymond, Judith, Fernández, Luis E, Mesa, Circe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019907/ https://www.ncbi.nlm.nih.gov/pubmed/24829762 http://dx.doi.org/10.1186/2051-1426-2-5 |
Ejemplares similares
-
Ganglioside containing nano-proteoliposome dampens myeloid-derived suppressor cells function and ability to cross-present tumor antigens: a new approach to recover CTL function on tumor bearing individuals
por: Fernández, Audry, et al.
Publicado: (2013) -
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator
por: Oliver, Liliana, et al.
Publicado: (2022) -
Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade
por: Kwong, Tsz Tung, et al.
Publicado: (2020) -
Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
por: Chevolet, Ines, et al.
Publicado: (2015) -
Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?
por: Escors, David, et al.
Publicado: (2013)